Loading…
Cognition Therapeutics, Inc. is projected to rise to $1.22 by 2027, a +3% move from its current price of $1.19. CGTX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.13 | $1.19 | $1.25 | +0.07% |
| May 30 | $1.11 | $1.19 | $1.28 | +0.15% |
| May 31 | $1.10 | $1.19 | $1.30 | +0.22% |
| Jun 1 | $1.08 | $1.19 | $1.32 | +0.29% |
| Jun 2 | $1.07 | $1.19 | $1.33 | +0.37% |
| Jun 3 | $1.06 | $1.20 | $1.35 | +0.44% |
| Jun 4 | $1.05 | $1.20 | $1.36 | +0.52% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.05 | $1.20 | $1.36 | +0.52% |
| Week 2 | $1.00 | $1.20 | $1.44 | +1.03% |
| Week 3 | $0.9671 | $1.21 | $1.51 | +1.55% |
| Week 4 | $0.9391 | $1.21 | $1.57 | +2.08% |
| Week 5 | $0.9157 | $1.22 | $1.63 | +2.60% |
| Week 6 | $0.8955 | $1.23 | $1.68 | +3.13% |
| Week 7 | $0.8777 | $1.23 | $1.73 | +3.66% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company that engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies.
Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
CGTX is currently priced at $1.26 with a market capitalization of $112.77M and a market position that places it at rank 4176 by market cap.
The near-term technical backdrop shows a neutral stance with a 30-day price view that sits between a low of $0.9009 and a high of $1.76. The stock’s volatility profile is elevated, with annualized volatility at 100%.
The 30-day technical snapshot features RSI(14) at 60, with SMA50 at $1.10 and SMA200 at $1.44. Key near-term support sits at $0.974 and resistance at $1.29, framing a modest range around the current level.
Looking ahead, forecasts imply a path of upside over the multi-year horizon, with 2026 around $1.26 on average, and longer-horizon milestones showing meaningful appreciation: 2030 average $1.84, 2040 average $4.87, and 2050 average $6.60, accompanying gains in the corresponding ROI figures.
A major floor 50.0% below — a decisive break under it would weaken the trend.
The nearest floor, 8.4% below — buyers have tended to step in here.
The nearest ceiling, 8.4% above — a clean break opens room to run.
A major ceiling 22.7% above — clearing it would confirm fresh momentum.
Key CGTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CGTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.25 | Sell | $1.22 | Sell |
| MA 10 | $1.20 | Sell | $1.21 | Sell |
| MA 20 | $1.21 | Sell | $1.19 | Sell |
| MA 50 | $1.10 | Buy | $1.16 | Buy |
| MA 100 | $1.15 | Buy | $1.19 | Buy |
| MA 200 | $1.44 | Sell | $1.20 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.71 | Neutral |
| Stoch RSI (14) | 43.81 | Neutral |
| CCI (20) | -27.11 | Neutral |
| Williams %R (14) | -50.00 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -1.65 | Sell |
| Bollinger %B (20,2) | 0.42 | Neutral |
| Stochastic %K (14) | 50.00 | Neutral |
| TRIX (15) | 0.38 | Buy |
| Awesome (5,34) | 0.07 | Buy |
| Ultimate (7,14,28) | 53.38 | Neutral |
| Momentum (10) | 0.01 | Buy |
| Aroon Osc (25) | 8.00 | Buy |
| Hull MA (9) | 1.26 | Sell |
| ADX (14) | 12.10 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is neutral, with RSI(14) at 60 and the moving averages showing a convergence around the current level. The SMA50 sits at $1.10 and the SMA200 at $1.44, highlighting a cautious posture near the price zone.
In the near term, traders should note support at $0.974 and resistance at $1.29. The 30-day range spans $0.9009 to $1.76, underscoring evolving volatility in the shorter window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.595 | $1.19 | $1.63 | 0% | Neutral | |
| $0.8955 | $1.22 | $1.80 | +3% | Neutral | |
| $0.842 | $1.21 | $1.89 | +2% | Neutral | |
| $0.9041 | $1.36 | $2.22 | +14% | Neutral | |
| $1.02 | $1.60 | $2.71 | +35% | Bullish | |
| $1.22 | $1.99 | $3.47 | +67% | Bullish | |
| $1.36 | $2.30 | $4.13 | +93% | Bullish | |
| $1.30 | $2.28 | $4.21 | +92% | Bullish | |
| $1.30 | $2.36 | $4.44 | +98% | Bullish | |
| $1.19 | $2.22 | $4.28 | +87% | Bullish | |
| $1.88 | $4.12 | $8.67 | +246% | Bullish | |
| $2.52 | $5.60 | $12.89 | +371% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.595 | $1.19 | $1.40 | +0.00% |
| June 2026 | $1.00 | $1.20 | $1.48 | +0.70% |
| July 2026 | $1.05 | $1.27 | $1.61 | +6.19% |
| August 2026 | $1.03 | $1.27 | $1.63 | -0.22% |
| September 2026 | $0.997 | $1.24 | $1.61 | -2.62% |
| October 2026 | $1.02 | $1.28 | $1.69 | +3.17% |
| November 2026 | $1.02 | $1.29 | $1.73 | +1.13% |
| December 2026 | $0.947 | $1.20 | $1.63 | -6.63% |
Click any year to see its month-by-month CGTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Cognition Therapeutics, Inc.'s 2026 outlook centres on $1.19, within a $0.595 to $1.63 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CGTX could reach as high as $1.80, with a base case around $1.22 and support toward $0.8955 — roughly +3% from $1.19. Price action looks broadly range-bound.
Expect CGTX to range from $0.842 to $1.89 through 2028. The $1.21 average target implies a +2% move from current prices. That is -1% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The CGTX price prediction for 2029 points to an average of $1.36 (low $0.9041, high $2.22) — a potential gain of +14% on today's $1.19. Price action looks broadly range-bound.
In 2030, CGTX is projected to trade between $1.02 and $2.71, averaging $1.60 — a potential gain of +35% from today's $1.19. That is up +18% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Cognition Therapeutics, Inc.'s 2031 outlook centres on $1.99, within a $1.22 to $3.47 range. That is up +24% on the projected 2030 average. That marks a +67% change versus current levels. Momentum favours further upside here.
By 2032, CGTX could reach as high as $4.13, with a base case around $2.30 and support toward $1.36 — roughly +93% from $1.19. Buyers look set to stay in control over this stretch.
Expect CGTX to range from $1.30 to $4.21 through 2033. The $2.28 average target implies a +92% move from current prices. That is -1% versus the projected 2032 average. Momentum favours further upside here.
The CGTX price prediction for 2034 points to an average of $2.36 (low $1.30, high $4.44) — a potential gain of +98% on today's $1.19. Buyers look set to stay in control over this stretch.
In 2035, CGTX is projected to trade between $1.19 and $4.28, averaging $2.22 — a potential gain of +87% from today's $1.19. That is -6% versus the projected 2034 average. Momentum favours further upside here.
Cognition Therapeutics, Inc.'s 2040 outlook centres on $4.12, within a $1.88 to $8.67 range. That is up +85% on the projected 2035 average. That marks a +246% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CGTX could reach as high as $12.89, with a base case around $5.60 and support toward $2.52 — roughly +371% from $1.19. Momentum favours further upside here.
Investing $1,000 in CGTX today (≈ 840.336134 CGTX) could be worth
$4,709.76
+$3,709.76 (+371%) by 2050 · US Dollar
Based on the average projected CGTX price of $5.6 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CGTXwould be worth at today's price.
$1,000 invested in CGTX on May 27, 2025 (≈ 3,861.003811 CGTX) would be worth
$4,594.59
+$3,594.59 (+359.5%) today · 4.59× · US Dollar
Based on a CGTX entry price of $0.259 vs. today's $1.19.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.29 | $922.48 | -7.8% |
| 1 month ago | $1.28 | $929.69 | -7.0% |
| 3 months ago | $1.16 | $1,025.86 | +2.6% |
| 6 months ago | $1.74 | $683.91 | -31.6% |
| 1 year ago | $0.259 | $4,594.59 | +359.5% |
| All time (4.6y) ago | $12.77 | $93.19 | -90.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CGTX forecast.
Our base-case forecast reaches $2.40 around 2040.
Implied market cap at $2.40: $214.8M
The year-by-year forecast paints an upside trajectory across the coming years. For 2026 the average price is $1.26 with a min of $0.595 and a max of $1.72 (ROI 0, sentiment NEUTRAL). By 2027 the average is $1.32 (min $0.9615, max $1.97, ROI 5.1, sentiment NEUTRAL), and 2028 shows an average of $1.31 (min $0.9023, max $2.08, ROI 4.3, sentiment NEUTRAL).
The 2029 forecast features an average of $1.49 (min $0.9751, max $2.46, ROI 18.3, sentiment NEUTRAL), with 2030 projecting an average of $1.84 (min $1.15, max $3.16, ROI 46, sentiment BULLISH).
From 2031 onward, the forecast remains bullish, with 2031 average $2.26 (min $1.36, max $4.02, ROI 79.6), 2032 average $2.62 (min $1.51, max $4.78, ROI 107.5), 2033 average $2.63 (min $1.47, max $4.94, ROI 109), 2034 average $2.68 (min $1.44, max $5.14, ROI 112.4), and 2035 average $2.52 (min $1.31, max $4.95, ROI 100.2).
The long horizon reinforces stronger upside with 2040 average $4.87 (min $2.19, max $10.48, ROI 286.5, sentiment BULLISH) and 2050 average $6.60 (min $2.97, max $15.17, ROI 423.5, sentiment BULLISH). These figures reflect a rising price trajectory alongside rising confidence in longer-dated fundamentals, though they remain estimates and are not guarantees.
Tap a question to reveal the answer.
2030 forecast shows an average price of $1.84 with a min of $1.15 and a max of $3.16; ROI is 46 and the sentiment is BULLISH.
The forecast grows from a 2026 average of $1.26 (ROI 0) to higher levels later, with 2029 at $1.49 (ROI 18.3) and 2030 at $1.84 (ROI 46). From 2031 onward the outlook turns more bullish, with 2040 at $4.87 (ROI 286.5) and 2050 at $6.60 (ROI 423.5). These are estimates, not guarantees.
Yes. The 2040 forecast shows an average price of $4.87, with a max of $10.48 (ROI 286.5, sentiment BULLISH). The year 2030 max is $3.16, so the $4 level is not forecast for 2030 but is possible by 2040 in the provided outlook.
The figures are forward-looking estimates across multiple years and are not guaranteed. The forecast shows variability in min/max prices and ROI across years, and actual results can differ.
Annualized volatility is 100%, reflecting substantial price movement potential over time.
Cognition Therapeutics, Inc. Community Discussion
0Share your Cognition Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.